Redbud Labs specializes in developing advanced microfluidic technologies designed to enhance sample preparation and assay automation for low to medium throughput applications. The company serves clients in the biotechnology and life sciences sectors, including research institutions, diagnostic labs, and companies involved in molecular and cellular assays. Operating in the niche market of microfluidics, Redbud Labs leverages its proprietary NAxtract platform, which utilizes a powerful new chip to maximize the performance of magnetic bead reactions in microfluidic cartridges. This platform is compatible with a wide range of analytes, from nucleic acids to proteins, making it versatile for various applications. The business model focuses on partnering with firms that have sample prep kits needing automation and those offering systems for downstream sample processing and analysis. Revenue is generated through the sale of its microfluidic platforms and associated consumables, as well as through strategic partnerships and collaborations.

Keywords: microfluidics, sample preparation, assay automation, biotechnology, life sciences, NAxtract, magnetic bead reactions, molecular assays, cellular assays, diagnostic labs.